{"filing":{"accession_number":"0001104659-26-094041","cik":"0001819411","ticker":"GANX","company_name":"Gain Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"ganx-20260811x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926094041/ganx-20260811x8k.htm"},"events":[{"id":26920,"run_id":24487,"accession_number":"0001104659-26-094041","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Gain Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release includes condensed consolidated statements of operations and balance sheets, along with detailed discussion of R\u0026D expenses ($2.1M), G\u0026A expenses ($2.5M), net loss per share ($0.11), and cash position ($13.1M). This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28219,"accession_number":"0001104659-26-094041","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Gain Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release includes condensed consolidated statements of operations and balance sheets, along with detailed discussion of R\u0026D expenses ($2.1M), G\u0026A expenses ($2.5M), net loss per share ($0.11), and cash position ($13.1M). This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:15:14.043822+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28219,"accession_number":"0001104659-26-094041","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Gain Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release includes condensed consolidated statements of operations and balance sheets, along with detailed discussion of R\u0026D expenses ($2.1M), G\u0026A expenses ($2.5M), net loss per share ($0.11), and cash position ($13.1M). This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:15:14.043822+00:00","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-08-11"}]}